LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

D.M. O'Malley; A. Oaknin; B.J. Monk; A. Leary; F. Selle; J. Alexandre; L.M. Randall; C. Rojas; M. Neffa; A. Kryzhanivska; L. Gladieff; D. Berton; T. Meniawy; I. Lugowska; I. Bondarenko; K.N. Moore; W.I. Ortuzar Feliu; M. Ancukiewicz; I. Shapiro; I.L. Ray-Coquard

doi:10.1016/j.annonc.2020.08.2264

LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

D.M. O'Malley
, A. Oaknin
, B.J. Monk
, A. Leary
, F. Selle
, J. Alexandre
, L.M. Randall
, C. Rojas
, M. Neffa
, A. Kryzhanivska
, L. Gladieff
, D. Berton
, T. Meniawy
, I. Lugowska
, I. Bondarenko
, K.N. Moore
, W.I. Ortuzar Feliu
, M. Ancukiewicz
, I. Shapiro
, I.L. Ray-Coquard

Universidad de los Andes

Research output: Contribution to conference › Poster › peer-review

Abstract

Background: Second line treatment for R/M CC continues to be a high unmet clinical need. We present data from 2 ph2 trials, of single-agent balstilimab (bal) and in combination with zalifrelimab (zal) in R/M CC.

Original language	Spanish (Chile)
Pages	S1164-S1165
DOIs	https://doi.org/10.1016/j.annonc.2020.08.2264
State	Published - Sep 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.annonc.2020.08.2264

Cite this

O'Malley, D. M., Oaknin, A., Monk, B. J., Leary, A., Selle, F., Alexandre, J., Randall, L. M., Rojas, C., Neffa, M., Kryzhanivska, A., Gladieff, L., Berton, D., Meniawy, T., Lugowska, I., Bondarenko, I., Moore, K. N., Ortuzar Feliu, W. I., Ancukiewicz, M., Shapiro, I., & Ray-Coquard, I. L. (2020). LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials. S1164-S1165. https://doi.org/10.1016/j.annonc.2020.08.2264

@conference{3ba3de48481144b2a8a8c031002f492a,

title = "LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials",

abstract = "Background: Second line treatment for R/M CC continues to be a high unmet clinical need. We present data from 2 ph2 trials, of single-agent balstilimab (bal) and in combination with zalifrelimab (zal) in R/M CC.",

author = "D.M. O'Malley and A. Oaknin and B.J. Monk and A. Leary and F. Selle and J. Alexandre and L.M. Randall and C. Rojas and M. Neffa and A. Kryzhanivska and L. Gladieff and D. Berton and T. Meniawy and I. Lugowska and I. Bondarenko and K.N. Moore and \{Ortuzar Feliu\}, W.I. and M. Ancukiewicz and I. Shapiro and I.L. Ray-Coquard",

year = "2020",

month = sep,

doi = "10.1016/j.annonc.2020.08.2264",

language = "Espa{\~n}ol (Chile)",

pages = "S1164--S1165",

}

O'Malley, DM, Oaknin, A, Monk, BJ, Leary, A, Selle, F, Alexandre, J, Randall, LM, Rojas, C, Neffa, M, Kryzhanivska, A, Gladieff, L, Berton, D, Meniawy, T, Lugowska, I, Bondarenko, I, Moore, KN, Ortuzar Feliu, WI, Ancukiewicz, M, Shapiro, I & Ray-Coquard, IL 2020, 'LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials', pp. S1164-S1165. https://doi.org/10.1016/j.annonc.2020.08.2264

TY - CONF

T1 - LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

AU - O'Malley, D.M.

AU - Oaknin, A.

AU - Monk, B.J.

AU - Leary, A.

AU - Selle, F.

AU - Alexandre, J.

AU - Randall, L.M.

AU - Rojas, C.

AU - Neffa, M.

AU - Kryzhanivska, A.

AU - Gladieff, L.

AU - Berton, D.

AU - Meniawy, T.

AU - Lugowska, I.

AU - Bondarenko, I.

AU - Moore, K.N.

AU - Ortuzar Feliu, W.I.

AU - Ancukiewicz, M.

AU - Shapiro, I.

AU - Ray-Coquard, I.L.

PY - 2020/9

Y1 - 2020/9

N2 - Background: Second line treatment for R/M CC continues to be a high unmet clinical need. We present data from 2 ph2 trials, of single-agent balstilimab (bal) and in combination with zalifrelimab (zal) in R/M CC.

AB - Background: Second line treatment for R/M CC continues to be a high unmet clinical need. We present data from 2 ph2 trials, of single-agent balstilimab (bal) and in combination with zalifrelimab (zal) in R/M CC.

UR - https://www.mendeley.com/catalogue/aef6cf03-b4cf-3470-9e71-97027e86ab16/

U2 - 10.1016/j.annonc.2020.08.2264

DO - 10.1016/j.annonc.2020.08.2264

M3 - Póster

SP - S1164-S1165

ER -

LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

Abstract

UN SDGs

Access to Document

Other files and links

Cite this